ecancermedicalscience

Erratum

Comparative efficacy of modified FOLFIRINOX, gemcitabine plus capecitabine and gemcitabine plus nab-paclitaxel as adjuvant treatment for resected pancreatic cancer: a Bayeasian network meta-analysis

12 Oct 2021
Victor Hugo Fonseca de Jesus, Rachel P Riechelmann

Throughout the text, please consider that the primary outcome of the PRODIGE24 trial was disease-free survival, and not overall survival.

Related Articles

Ally H Mwanga, Jeanine Justiniano, Eric M Mbuguje, Balowa Musa, Deogratius B Mwanakulya, Andrew Swallow, Edith Kimambo, Eva Uiso, Swaleh Pazi, Latifa Rajab, Nashivai E Kivuyo, Larry Akoko, Azza Naif, Advera Ngaiza, Sara Nyagabona, Jerry Ndumbalo, Amos R Mwakigonja, Jim E Littlejohn, Seif Wibonela, Cameron E Gaskill
Dario Cattel, Rosario De Feo, Francesco Sabbatino, Stefano Pepe, Alessandro Puzziello
Hani Shihadeh, Ahmad Yousef, Ahmad Al-Leimon, Hussein Abu-Rumman, Laith Kreshan
Simone P S Lima, Rafael Fernandes-Ferreira, Beatriz J Brait, Franciana L Aguiar, Marcela A S Pinhel, Abner dos Santos Abreu, Renato F Silva, Rita C M A Silva, Doroteia R S Souza